Search

Displaying results 1001 - 1010 of 6076 in total
  1. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.

  2. Drug

    Iobenguane

    go.drugbank.com/drugs/DB06704
    ApprovedInvestigational

    The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline.

  3. Drug

    Zuclopenthixol

    go.drugbank.com/drugs/DB01624
    ApprovedInvestigational

    Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.

  4. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    [L31253] In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended voclosporin be granted marketing authorization for use in combination with [mycophenolate mofetil] … for the treatment of adult patients with active lupus nephritis.

  5. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the … Moreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well [F3].

  6. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.

    Categories: Preparations for Treatment of Wounds and Ulcers
  7. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    [A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity.

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  8. Drug

    Promethazine

    go.drugbank.com/drugs/DB01069
    ApprovedInvestigational

    [A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.

    Categories: Antihistamines for Topical Use, Antihistamines for Systemic Use
  9. Drug

    Anethole trithione

    go.drugbank.com/drugs/DB13853
    Approved

    A32618, A32620, A32621], to demonstrating an ability to inhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes [A32619], and even being used as an adjunctive therapy for … Unfortunately, many of the specific mechanisms of action to these activities have yet to be formally elucidated, which means that while studies are ongoing, ATT itself is not necessarily formally indicated for

  10. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]